

Arguments/Remarks

Claims 1-8, and 11 are presently pending in the application. Reconsideration is respectfully requested.

Rejections under 35 USC §103

Claims 1-8 and 11 have been rejected under 35 USC §103 as being obvious over WO 02/22597 to Buerger et al. More particularly, the Examiner states that Buerger teaches substituted pyrimidine compounds which have tyrosine kinase inhibitory activity, the instantly claimed compounds only differing in that R3 is alkyl, as compared to hydrogen on the terminal phenyl ring.

Applicants submit herewith a declaration under 37 C.F.R. 132 rebutting the obvious rejection. Withdrawal and reconsideration are respectfully requested.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.  
220 Massachusetts Avenue  
Cambridge, MA 02139  
(617) 871-7347

  
Mark E. Baron  
Attorney for Applicants  
Reg. No. 46,150

Date: 21 August 2009